Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027

RECURSION PHARMACEUTICALS, INC.

2024-FY EPS reported -$1.69 revenue$58,839,000

Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.
Q4 revenue $4.5M (down 59% YoY); FY2024 revenue $58.8M (up 32% YoY). Pro forma revenue $82.6M.
Operating cash outflow $115.4M in Q4; $359.2M for FY2024. Exscientia cash burn ~$184M pre-acquisition.
Completed Exscientia merger Nov 2024; maintaining guidance of at least $100M in annual synergies.
Pipeline advanced: REC-617 showed durable partial response; three new clinical trials initiated (DAHLIA, TUPELO, ALDER).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.